Compare Medpace Holdings Inc (MEDP) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs State Street PDR S&P Retail ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while State Street PDR S&P Retail ETF trades at $84.09 (market cap $389.66M). The key difference: Medpace Holdings Inc is far larger — about 43.2× State Street PDR S&P Retail ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| MEDP | XRT | |
|---|---|---|
Market Cap | $16.82B | $389.66M |
Volume | 223,093 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $92.35 |
52-Week Low | $393.42 | $77.28 |
Typical Hold Time | 14 Days | 45 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
XRT, the SPDR S&P Retail ETF, trades at $83.91, up 1.21% on the day. The technical outlook is mixed with a bullish overall signal but bearish moving averages and an overbought RSI_6 at 84.45. Recent retail sales data shows volatility, with August rebounding 1.2% after a July decline. The ETF's fundamentals are not detailed in the snapshot, but it tracks the retail sector, facing headwinds from inflation and interest rates.
The outlook for XRT is cautious. While holiday sales projections exceed $1 trillion, macroeconomic pressures and analyst skepticism suggest potential underperformance. Key risks include consumer sentiment shifts and oil price volatility. Investors should weigh sector exposure against broader market alternatives like IVV.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
